Cabaletta Bio, Inc. Common Stock (CABA)
Cabaletta Bio, Inc. is a biotechnology company focused on developing engineered T cell therapies for autoimmune diseases. Its platform aims to selectively target and deplete pathogenic B cells responsible for autoimmune conditions, utilizing proprietary technologies to improve the specificity and safety of treatments.
Company News
Cabaletta Bio announces positive clinical data for its rese-cel therapy in patients with myositis, lupus, and scleroderma, with most patients achieving clinically meaningful responses while off immunomodulators and steroids. The company plans to initiate registrational trials and engage with the FDA on regulatory pathways.
US stock futures are pointing to a higher open on Friday as investors look to end November on a positive note. Analysts suggest that December has historically been a strong month for markets, with only one instance of it being the worst month in the last 95 years.
Discover the upcoming events and earnings reports in the financial market, including notable companies like Disney, Tyson Foods, and Uber.
Shares of small biotech companies involved in CAR-T therapies plunged Tuesday as the FDA said it was investigating potential cancer risks.
Here is how Cabaletta Bio, Inc. (CABA) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.